Incyte Corporation and Enable Injections announced a strategic partnership to develop and commercialize the enFuse® On‑Body Delivery System for Incyte’s investigational mutant calreticulin (mutCALR) selective monoclonal antibody, INCA033989, for essential thrombocythemia and myelofibrosis.
Under the agreement, Incyte receives a worldwide exclusive license to use the enFuse technology with INCA033989, with the option to expand to additional assets and indications. The partnership includes an upfront technology access fee, milestone payments tied to pre‑clinical, clinical, and regulatory milestones, and a transfer price for clinical and commercial supply of enFuse devices.
Enable’s enFuse system, which received FDA approval for a combination product in 2023 and an EU MDR CE Mark in March 2025, is designed to deliver large volumes of biologics subcutaneously, enabling at‑home self‑administration and greater patient convenience. Bill Meury, President and CEO of Incyte, said the collaboration “will accelerate the delivery of a first‑in‑class therapy and expand our portfolio beyond our core JAK inhibitor products.” Michael D. Hooven, Chairman and CEO of Enable Injections, added that the partnership “will bring a patient‑centric solution to a critical unmet need.”
The partnership is expected to enhance Incyte’s commercial capabilities, open new revenue streams, and diversify the company’s pipeline beyond its established JAK inhibitor franchise.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.